Omaha, NE Clinical Trials Report — April 2026

For Omaha residents considering participation in clinical research, April 2026 presents both urgent deadlines and new opportunities. A total of 26 clinical trials are slated to conclude enrollment within the next 90 days, meaning interested individuals should act quickly to explore these options. Notably, 5 of these rapidly closing studies are still actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Upcoming Deadlines for Clinical Trial Participation

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cardiovascular and oncological conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Heart failure (2 trials)
• Parkinson's disease (2 trials)
• Atrial fibrillation (1 trial)
• Cancer harboring BRAF alterations (1 trial)
• Cancer weight loss (1 trial)
• Chronic stress (1 trial)
• Cryptogenic stroke (1 trial)
• Colorectal cancer (1 trial)
• Dermatitis atopic (1 trial)
• Endometrial adenocarcinoma (1 trial)

This month, Omaha saw the opening of 7 new clinical trials, matching the number of trials that launched in March 2026. This consistent pace of new research opportunities contributes to the city's robust medical research landscape, which currently features 582 clinical trials recruiting across 223 research facilities.

New Research Opportunities in Omaha

April brings several notable new trials to Omaha, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study, aiming for 750 participants, investigates whether methylprednisolone administered before surgery can reduce side effects like infections and shorten hospital stays.
• Caliway Biopharmaceuticals Co., Ltd. is launching NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )." This important Phase 3, randomized, double-blinded, placebo-controlled study will evaluate CBL-514 injection for reducing abdominal subcutaneous fat in 320 participants.
• Eccogene is initiating NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial." This Phase 2 study, designed for 160 participants, aims to evaluate the effect of oral ECC4703 on body weight reduction and, in a sub-study, on liver fat content.

New trials this month are exploring a range of conditions, including adult obesity, developmental language disorder, diffuse large b-cell lymphoma, hepatectomy, motor function, older adults (65-85 years), subcutaneous fat, and weight management. Drug trials account for 4 of the new studies, with behavioral, device, other, and radiation trials each contributing 1 new study.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to medical research. 5 of the 7 new trials launched this month are actively seeking healthy volunteers. Across Omaha, a total of 51 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical advancements.

Omaha's Leading Research Institutions

Omaha is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Nebraska Medical Center (213 trials)
• Alegent Health Bergan Mercy Medical Center (42 trials)
• Nebraska Medicine-Village Pointe (40 trials)
• Creighton University Medical Center (37 trials)
• Alegent Health Lakeside Hospital (36 trials)
• Alegent Health Immanuel Medical Center (36 trials)
• Nebraska Cancer Specialists (36 trials)
• Nebraska Methodist Hospital (33 trials)
• Children's Hospital and Medical Center of Omaha (30 trials)

The University of Nebraska Medical Center leads the city's research efforts by a significant margin, offering a broad spectrum of research opportunities. Other facilities like Alegent Health and Nebraska Medicine also contribute substantially to Omaha's clinical trial landscape.

Eligibility and Broader Participation

Participation in clinical trials is open to a diverse range of individuals. Of the new trials launched this month, 1 includes children, and 5 include older adults, ensuring that various age groups have opportunities to contribute to medical science. Academic institutions like the University of Nebraska and the University of Colorado, Denver, along with industry sponsors like Caliway Biopharmaceuticals Co., Ltd. and Eccogene, are driving these new research efforts.

Expanding Your Search: Nearby Options

While Omaha offers a wide array of clinical trial opportunities, individuals may also find options in nearby communities within Nebraska. Cities with active trials include Lincoln (1 trial) and Norfolk (1 trial). These nearby options provide additional avenues for those interested in participating in research close to home.

As we move further into spring, Omaha's research community continues to advance medical knowledge, with ongoing enrollment in these significant trials and the continuous exploration of new therapeutic strategies. The opportunity to contribute to future health treatments remains strong for residents.